PortfoliosLab logoPortfoliosLab logo
CGON vs. ARTV
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

CGON vs. ARTV - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in CG Oncology, Inc (CGON) and Artiva Biotherapeutics, Inc (ARTV). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, CGON achieves a 33.74% return, which is significantly lower than ARTV's 60.14% return.


CGON

1D
-6.25%
1M
-16.21%
YTD
33.74%
6M
34.23%
1Y
108.84%
3Y*
5Y*
10Y*

ARTV

1D
-7.91%
1M
-36.39%
YTD
60.14%
6M
105.69%
1Y
254.12%
3Y*
5Y*
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

CGON vs. ARTV - Yearly Performance Comparison


2026 (YTD)20252024
CGON
CG Oncology, Inc
33.74%44.77%-18.57%
ARTV
Artiva Biotherapeutics, Inc
60.14%-57.44%-16.00%

Correlation

The correlation between CGON and ARTV is 0.33, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.33

Correlation (All Time)
Calculated using the full available price history since Jul 22, 2024

0.34

Fundamentals

Market Cap

CGON:

$4.69B

ARTV:

$169.54M

EPS

CGON:

-$1.61

ARTV:

-$3.55

PB Ratio

CGON:

4.30

ARTV:

1.93

Total Revenue (TTM)

CGON:

$5.07M

ARTV:

$0.00

Gross Profit (TTM)

CGON:

-$2.54M

ARTV:

$0.00

EBITDA (TTM)

CGON:

-$191.51M

ARTV:

-$90.10M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


CG Oncology, Inc

Artiva Biotherapeutics, Inc

Return for Risk

CGON vs. ARTV — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CGON
CGON Risk / Return Rank: 8787
Overall Rank
CGON Sharpe Ratio Rank: 8686
Sharpe Ratio Rank
CGON Sortino Ratio Rank: 8787
Sortino Ratio Rank
CGON Omega Ratio Rank: 8282
Omega Ratio Rank
CGON Calmar Ratio Rank: 9090
Calmar Ratio Rank
CGON Martin Ratio Rank: 9393
Martin Ratio Rank

ARTV
ARTV Risk / Return Rank: 8787
Overall Rank
ARTV Sharpe Ratio Rank: 7878
Sharpe Ratio Rank
ARTV Sortino Ratio Rank: 9191
Sortino Ratio Rank
ARTV Omega Ratio Rank: 8787
Omega Ratio Rank
ARTV Calmar Ratio Rank: 9191
Calmar Ratio Rank
ARTV Martin Ratio Rank: 8686
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CGON vs. ARTV - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for CG Oncology, Inc (CGON) and Artiva Biotherapeutics, Inc (ARTV). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


CGONARTVDifference

Sharpe ratio

Return per unit of total volatility

1.93

1.36

+0.57

Sortino ratio

Return per unit of downside risk

2.92

3.41

-0.49

Omega ratio

Gain probability vs. loss probability

1.33

1.40

-0.06

Calmar ratio

Return relative to maximum drawdown

4.68

5.23

-0.55

Martin ratio

Return relative to average drawdown

15.68

9.71

+5.97

CGON vs. ARTV - Sharpe Ratio Comparison

The current CGON Sharpe Ratio is 1.93, which is higher than the ARTV Sharpe Ratio of 1.36. The chart below compares the historical Sharpe Ratios of CGON and ARTV, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


CGONARTVDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

1.93

1.36

+0.57

Sharpe Ratio (All Time)

Calculated using the full available price history

0.29

-0.16

+0.45

Drawdowns

CGON vs. ARTV - Drawdown Comparison

The maximum CGON drawdown since its inception was -67.47%, smaller than the maximum ARTV drawdown of -90.71%. Use the drawdown chart below to compare losses from any high point for CGON and ARTV.


Loading charts...

Drawdown Indicators


CGONARTVDifference

Max Drawdown

Largest peak-to-trough decline

-67.47%

-90.71%

+23.24%

Max Drawdown (1Y)

Largest decline over 1 year

-24.96%

-48.92%

+23.96%

Current Drawdown

Current decline from peak

-24.96%

-56.60%

+31.64%

Average Drawdown

Average peak-to-trough decline

-25.93%

-58.37%

+32.44%

Ulcer Index

Depth and duration of drawdowns from previous peaks

7.45%

26.36%

-18.91%

Volatility

CGON vs. ARTV - Volatility Comparison

The current volatility for CG Oncology, Inc (CGON) is 14.68%, while Artiva Biotherapeutics, Inc (ARTV) has a volatility of 28.84%. This indicates that CGON experiences smaller price fluctuations and is considered to be less risky than ARTV based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


CGONARTVDifference

Volatility (1M)

Calculated over the trailing 1-month period

14.68%

28.84%

-14.16%

Volatility (6M)

Calculated over the trailing 6-month period

41.79%

105.01%

-63.22%

Volatility (1Y)

Calculated over the trailing 1-year period

56.79%

187.52%

-130.73%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

64.24%

159.55%

-95.31%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

64.24%

159.55%

-95.31%

Dividends

CGON vs. ARTV - Dividend Comparison

Neither CGON nor ARTV has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

CGON vs. ARTV - Financials Comparison

This section allows you to compare key financial metrics between CG Oncology, Inc and Artiva Biotherapeutics, Inc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.005.00M10.00M15.00M20.00M25.00M2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober2026
1.08M
0
(CGON) Total Revenue
(ARTV) Total Revenue
Values in USD except per share items

Frequently Asked Questions


CGON and ARTV have a correlation of 0.33, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

ARTV has higher volatility (28.84%) compared to CGON (14.68%). In terms of maximum drawdown, CGON dropped -67.47% vs ARTV's -90.71%.

CGON currently has the higher Sharpe Ratio (1.93 vs 1.36), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for CGON and ARTV

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer